Specialized healthcare private equity firm Altaris has entered into a definitive agreement to acquire Simulations Plus, a global leader in model-informed and AI-accelerated drug development. The all-cash transaction, valued at approximately $375 million, marks a major programmatic move by Altaris to consolidate its footprint within the high-growth biopharma computational modeling, machine learning, and artificial intelligence sectors.
The documented per-share acquisition premiums, integrated downstream portfolio merger timelines, and core computational technology frameworks feature:
-
Transaction Valuation Parameters and Shareholder Consideration:
-
Per-Share Payouts: Under the definitive terms of the buyout unveiled in a June 16, 2026 release, Simulations Plus shareholders are entitled to receive $18.50 per share in cash upon the closing of the transaction.
-
Premium Inflexions: This consideration represents a 26% premium relative to the target company’s 60-day volume-weighted average share price established prior to the official execution of the buyout. Following the transaction’s close, Simulations Plus plans to maintain its long-standing corporate headquarters within Research Triangle Park, North Carolina.
-
-
Targeted Closing Timelines and Altaris Portfolio Combination Strategies:
-
Closing Windows: The transaction is projected to achieve final structural completion within the fourth quarter of fiscal year 2026, subject to customary regulatory clearances and closing conditions.
-
Downstream Mergers: Post-acquisition, Altaris plans to structurally integrate Simulations Plus with its existing corporate portfolio asset, Chemical Computing Group, an established provider of computer-aided molecular design software tailored for the pharmaceutical, biotechnology, and crop sciences sectors.
-
Altaris Financial Baseline: The New York City-based Altaris manages an equity capital base exceeding $9 billion, focusing its investment mandate exclusively across the healthcare landscape. The private equity firm has historically executed value-driven M&A campaigns spanning digital health, advanced medical imaging infrastructures, and generic pharmaceutical markets.
-
-
Three-Decade Modeling Legacy characterizing the Simulations Plus Infrastructure:
-
B2B Client Staging: Founded 30 years ago, Simulations Plus engineers specialized modeling and simulation software suites engineered to streamline the drug discovery process, optimize clinical development paths, and support rigorous regulatory submission dossiers. The firm’s enterprise platforms are systematically utilized by premier multinational biopharma organizations, consumer goods manufacturers, and global regulatory authorities.
-
Advanced Quantitative Frameworks: The target company’s proprietary software matrix integrates advanced artificial intelligence, machine learning algorithms, physiologically based pharmacokinetics (PBPK), and comprehensive population pharmacokinetic/pharmacodynamic (PK/PD) modeling techniques to accelerate translational medicine pipelines.
-